Compare GSK plc (GSK) vs Lithium Americas Corp (LAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Lithium Americas Corp — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Lithium Americas Corp trades at $2.35 (market cap $850.38M). The key difference: GSK plc is far larger — about 108× Lithium Americas Corp's market cap, and GSK plc pays a 3.9% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Lithium Americas Corp for 27 Days on average.
| GSK | LAC | |
|---|---|---|
Market Cap | $91.88B | $850.38M |
Volume | 7,730,529 | 8,804,637 |
Sector | Health | Basic Materials |
52-Week High | $61.18 | $10.05 |
52-Week Low | $43.24 | $2.35 |
Typical Hold Time | 93 Days | 27 Days |
Enterprise Value | $111.88B | $1.19B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Lithium Americas (LAC) trades at $2.36, down 2.07% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -9.56% and ROA at -3.99%, while maintaining strong analyst support with 7 buy ratings and a $4.00 consensus price target. Recent financing activities and Thacker Pass project development provide growth catalysts amid challenging lithium market conditions.
LAC presents a high-risk opportunity with significant upside potential from its Thacker Pass project execution, though negative cash flow and lithium price volatility create near-term headwinds. The stock trades at a discount to analyst targets but requires successful project ramp-up to justify valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →
